Tumor News and Research

RSS

Avastin and chemo combo may offer hope for glioblastoma multiforme patients

Brain cancer patients with the poorest prognosis -- those with a type of deadly tumor known as glioblastoma multiforme (GBM) -- may survive longer with a drug that chokes off a tumor's blood supply.

19 Oct 2007

Clinical trial to evaluate glioblastoma multiforme vaccine commences at NYU

A clinical trial evaluating a brain cancer vaccine in patients with newly diagnosed brain cancer has begun at NYU Medical Center.

19 Oct 2007

Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma

Portal venous tumor thrombus (PVTT) is a crucial factor that can worsen the prognosis of patients with hepatocellular carcinoma (HCC).

18 Oct 2007

Researchers improve accuracy of breast cancer prognoses

One of the many unknowns facing women who are diagnosed with breast cancer is predicting the likelihood that the cancer will spread to other parts of the body – metastasize.

17 Oct 2007

Existing drugs may be useful in treating brain tumors

Scientists have shown how developing brain tumors can turn an encounter with a signaling molecule from a fatal experience for the tumor cells into a cue for their own growth and multiplication.

17 Oct 2007

Is the spleen able to prohibit tumor cell proliferation?

Primary and metastatic tumors of the spleen are described as unusual, excluding involvement by lymphoma.

17 Oct 2007

Nanorods of gold blast tumor cells

Researchers have shown how tiny "nanorods" of gold can be triggered by a laser beam to blast holes in the membranes of tumor cells, setting in motion a complex biochemical mechanism that leads to a tumor cell's self-destruction.

17 Oct 2007

AngioGenex files patent on first small molecule Id-inhibitors

AngioGenex Inc. has identified and filed a patent application on small molecules that are potent inhibitors of the Id proteins.

17 Oct 2007

Dmp1 gene and lung cancer

The first research to show the involvement of a gene known as Dmp1 in human lung cancer will hopefully lead to an increased understanding on what goes wrong at the cellular level to cause the disease, according to researchers from Wake Forest University School of Medicine reporting in Cancer Cell .

16 Oct 2007

Researchers specifically manipulate tumor angiogenesis gene

Angiogenesis is a common process that is essential for tumor growth beyond 2 mm. Although numerous growth factors are involved, vascular endothelial growth factor (VEGF), particularly VEGF-A, has been shown to play an important role in tumor angiogenesis.

16 Oct 2007

New insight into Herceptin resistance in breast cancer

A new study provides important insight into the mechanisms involved in resistance to treatment of breast cancer patients with trastuzumab (Herceptin). The research, published by Cell Press in the October issue of the journal Cancer Cell , identifies markers that may help to identify patients who are unlikely to respond to trastuzumab treatment and provides a potential strategy for treating these patients.

16 Oct 2007

Enhanced DNA-repair mechanism can cause breast cancer

Although defects in the "breast cancer gene," BRCA1, have been known for years to increase the risk for breast cancer, exactly how it can lead to tumor growth has remained a mystery.

16 Oct 2007

A tumor marker Ca 19-9 in diabetics can lead to misdiagnosis of pancreatic cancer

Diabetes is increasing all over the world along with the increase of obesity and associated diseases and is a well-known risk factor for pancreatic cancer. The incidence of pancreatic cancer is also increasing and has one of the lowest survival rates of all cancers.

16 Oct 2007

Delisheng shows anti-cancer effects on hepatocellular carcinoma

Traditional Chinese medicine is world renowned. It has supernatural effects on some diseases, but the reason is still unknown. One such article was recently reported in the November 7 issue of the World Journal of Gastroenterology dealing with the great significance of a Chinese medicinal compound, "delisheng", for the therapy of HCC and its neoteric research method.

16 Oct 2007

Important insights into blood vessel formation

Researchers have identified a molecular pathway that plays a critical role in the growth of blood vessels.

15 Oct 2007

Cause and clinical outcome of portal vein thrombosis

Among the 118 patients with portal vein thrombosis, noncirrhotic and nontumoral extrahepatic portal vein obstruction are young and present with well tolerated bleed.

15 Oct 2007

New gene findings show that controls of lifespan and cancer have deep, common roots

A person is 100 times more likely to get cancer at age 65 than at age 35. But new research reported in the journal "Nature Genetics" identifies naturally occurring processes that allow many genes to both slow aging and protect against cancer in the much-studied C. elegans roundworm.

15 Oct 2007

Breast cancer radiation does not affect women's immune system

A new study shows that neither of two commonly used radiation treatments for early-stage, node-negative breast cancer has any effect on a woman's immune system, even though women who receive five-day partial-breast radiation therapy (MammoSite brachytherapy) (PBRT) have improved energy and quality of life compared to women who undergo six weeks of whole-breast radiation therapy (WBRT).

15 Oct 2007

AMDL submits data to FDA for clearance to market its diagnostic test to monitor colorectal cancer patients

AMDL, Inc., developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that it has filed with the U.S. Food & Drug Administration (FDA) for clearance to market its unique, proprietary DR-70 (FDP) ELISA tumor marker test for use as an aid in monitoring patients previously diagnosed with colorectal cancer. AMDL used the guidance provided at the meeting they had with the FDA on January 25, 2007.

15 Oct 2007

New research may show why some prostate cancer recurs after treatment

Cancer researchers have long worked to understand why some prostate cancers recur after the use of therapies designed to stop the production of testosterone and other androgens that fuel cancer cell growth.

12 Oct 2007